Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

This article discusses the enzyme pathways involved in androgenetic alopecia and the role of finasteride in reducing dihydrotestosterone levels to promote hair growth; it reports no new clinical results.

This study found that a 5-mg daily dose of transdermal testosterone cream in postmenopausal women restored testosterone levels to those typical of premenopausal women.

This study found that sulforaphane treatment enhanced hair regeneration in ob/ob mice by increasing DHT-degrading enzyme levels and lowering plasma testosterone and DHT.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study found that a polyherbal formulation of Trigonella foenum-graecum and Butea monosperma significantly promoted hair growth and reduced DHT levels in a chemotherapy-induced alopecia model.

This study found that Ficus carica extract enhanced fertility markers, including hormone levels and reproductive organ activity, in rats of both sexes, suggesting potential benefits for managing fertility issues.

This study found that HBV infection altered steroid metabolism in male mice, significantly increasing levels of dehydroepiandrosterone and reducing dihydrotestosterone, which may suppress viral replication by affecting HBV promoter activity.

In this study, creatine supplementation over 12 weeks showed no effect on androgen levels or hair follicle health in healthy young males, challenging the belief that creatine causes hair loss.

This study found that sleep deprivation in mice can trigger prostatitis by activating the cGAS-STING pathway due to reduced levels of dihydrotestosterone and melatonin, resulting in a pro-inflammatory environment, while recovery sleep can mitigate these effects.

In this case report, the researchers emphasize the importance of regular prostate exams and PSA tests for diabetic men, including those who are hypogonadal, because prostate cancer development is linked to intraprostatic dihydrotestosterone levels, not serum testosterone levels.

In this study, oral testosterone administered three times daily normalized serum testosterone levels in men with experimentally induced hypogonadism over nine days and significantly reduced SHBG.

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

This study found that combining oral testosterone with dutasteride increased testosterone bioavailability in hypogonadal men while suppressing dihydrotestosterone levels over a 28-day period.

In this study, exposure to the drug finasteride in Silurana tropicalis significantly increased testosterone levels in liver and testis tissues and altered gene expression related to male reproduction and oxidative stress.

In these aquatic laboratory studies, researchers found that Finasteride reduced dihydrotestosterone levels in fathead minnows and increased gene expression related to androgen pathways in both minnows and medaka, indicating potential conservation of pharmaceutical effects on androgen biosynthesis across different species.

In this laboratory study, finasteride administration in male rats lowered dihydrotestosterone levels and reduced c-Fos protein activation in brain tissue, indicating an impact on brain regions like the hippocampus, though these effects diminished after one month of withdrawing the drug.

This study reports that topical finasteride significantly reduced scalp and plasma dihydrotestosterone in men and women without altering serum testosterone levels, with promising preliminary results.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.

This study concluded that finasteride-induced DHT deficiency intensified constitutive iNOS expression in rat testicular and epididymal cells, suggesting a complex regulatory relationship needing further investigation.

In this review, the role of DHT in male-type obesity and metabolic diseases is discussed, with increased levels potentially exacerbating cardiovascular disease risk; the paper reports no new results.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

This study found that resveratrol significantly alleviated testicular damage in male rats caused by finasteride, which otherwise led to decreased testosterone levels and various histopathological alterations in the testes.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This study suggests that in gilthead seabream, DHT is involved in the onset of the meiotic phase of spermatogenesis and influences serum levels of E2 through regulation of aromatase activity.